Osteoporosis, OsteopeniaMYOIRISINNCT07519551
Serum Myostatin and Irisin Levels in Postmenopausal Women: Association With Bone Mineral Density and Muscle Strength
An observational study of Osteoporosis, Osteopenia, run by Kanuni Sultan Suleyman Training and Research Hospital.
Trial summary
This study aims to evaluate the relationship between serum myostatin and irisin levels and bone mineral density and muscle strength in postmenopausal women. Participants will be grouped according to bone mineral density as normal, osteopenic, or osteoporotic. Read more about this study
- Who is it for?
- Ages 50 to 65 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Osteoporosis, Osteopenia
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- 3 Apr 2026to 30 May 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 65 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population will consist of postmenopausal women aged between 50 and 65 years who attend the outpatient clinic and meet the inclusion criteria. Participants will be classified into normal, osteopenic, and osteoporotic groups based on bone mineral density measurements obtained by dual-energy X-ray absorptiometry (DEXA).
Who may be able to join
- Postmenopausal women aged between 50 and 65 years Availability of bone mineral density measurement by dual-energy X-ray absorptiometry (DEXA) Willingness to participate in the study
Who cannot join
- Presence of malignancy Chronic kidney disease Chronic liver disease Neuromuscular disorders Recent major surgery or trauma Use of medications affecting bone or muscle metabolism
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Evaluation of the Relationship Between Serum Myostatin and Irisin Levels and Bone Mineral Density and Muscle Strength in Postmenopausal Women
This study aims to evaluate the relationship between serum myostatin and irisin levels and bone mineral density and muscle strength in postmenopausal women. Participants will be grouped according to bone mineral density as normal, osteopenic, or osteoporotic. Serum myostatin and irisin levels will be measured, and muscle strength will be assessed using handgrip strength and the five times sit-to-stand test. The associations between biochemical and functional parameters will be analyzed.
Read the detailed description
This cross-sectional observational study aims to evaluate the relationship between serum myostatin and irisin levels and bone mineral density and muscle strength in postmenopausal women. Postmenopausal women aged between 50 and 65 years who meet the inclusion criteria will be enrolled in the study. Bone mineral density will be assessed using dual-energy X-ray absorptiometry (DEXA), and participants will be classified into three groups as normal, osteopenic, or osteoporotic according to T-scores.
Serum myostatin and irisin levels will be measured from venous blood samples collected after overnight fasting. Muscle strength will be evaluated using handgrip strength, and functional performance will be assessed with the five times sit-to-stand test. Demographic and clinical characteristics of the participants will also be recorded.
The relationships between serum myostatin and irisin levels and bone mineral density and muscle strength parameters will be analyzed using appropriate statistical methods.
- Conditions
- Osteoporosis, Osteopenia
- Medical subject headings
- Osteoporosis, Bone Diseases, Metabolic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Normal BMD | Postmenopausal women with normal bone mineral density based on dual-energy X-ray absorptiometry (DEXA) T-scores. | |
| Osteopenia | Postmenopausal women with osteopenia defined by dual-energy X-ray absorptiometry (DEXA) T-scores. | |
| Osteoporosis | Postmenopausal women with osteoporosis defined by dual-energy X-ray absorptiometry (DEXA) T-scores. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Relationship between serum myostatin and irisin levels and bone mineral density (T-score)
Serum myostatin and irisin levels will be measured from fasting venous blood samples, and bone mineral density will be assessed using dual-energy X-ray absorptiometry (DEXA). The relationship between these parameters will be evaluated.
Measured: Baseline
Secondary outcomes (2)
Relationship between serum myostatin and irisin levels and muscle strength
Muscle strength will be assessed using handgrip strength, and its relationship with serum myostatin and irisin levels will be evaluated.
Measured: Baseline
Comparison of serum myostatin and irisin levels among bone mineral density groups
Serum myostatin and irisin levels will be compared among normal, osteopenic, and osteoporotic groups defined by dual-energy X-ray absorptiometry (DEXA).
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Apr 2026
- Study start3 Apr 2026 (estimated)
- Primary completion15 May 2026 (estimated)
- Study completion30 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Osteoporosis, OsteopeniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Saglik Bilimleri Universitesi
- Responsible party
- Principal investigator, Zeynep Karakuzu Güngör, Kanuni Sultan Suleyman Training and Research Hospital
- Investigators
- Zeynep Karakuzu Güngör, M.D, Principal investigator, Saglik Bilimleri Universitesi
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07519551
- Sponsor's protocol ID
- MYO-IRISIN-BMD-2026-01
- Acronym
- MYOIRISIN
- Status last verified
- Apr 2026
- First submitted
- 2 Apr 2026
- Last updated
- 9 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Relationship Between Serum Myostatin and Irisin Levels and Bone Mineral Density and Muscle Strength in Postmenopausal Women
- ClinicalTrials.gov ID
- NCT07519551
- Acronym / sponsor ID
- MYOIRISIN / MYO-IRISIN-BMD-2026-01
- Conditions
- Osteoporosis, Osteopenia
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Kanuni Sultan Suleyman Training and Research HospitalUniversity, hospital or other
- Collaborators
- Saglik Bilimleri Universitesi
- Study start
- 3 Apr 2026 (estimated)
- Primary completion
- 15 May 2026 (estimated)
- Study completion
- 30 May 2026 (estimated)
- First posted
- 9 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the relationship between serum myostatin and irisin levels and bone mineral density and muscle strength in postmenopausal women. Participants will be grouped according to bone mineral density as normal, osteopenic, or osteoporotic. Serum myostatin and irisin levels will be measured, and muscle strength will be assessed using handgrip strength and the five times sit-to-stand test. The associations between biochemical and functional parameters will be analyzed.
Detailed description
This cross-sectional observational study aims to evaluate the relationship between serum myostatin and irisin levels and bone mineral density and muscle strength in postmenopausal women. Postmenopausal women aged between 50 and 65 years who meet the inclusion criteria will be enrolled in the study. Bone mineral density will be assessed using dual-energy X-ray absorptiometry (DEXA), and participants will be classified into three groups as normal, osteopenic, or osteoporotic according to T-scores.
Serum myostatin and irisin levels will be measured from venous blood samples collected after overnight fasting. Muscle strength will be evaluated using handgrip strength, and functional performance will be assessed with the five times sit-to-stand test. Demographic and clinical characteristics of the participants will also be recorded.
The relationships between serum myostatin and irisin levels and bone mineral density and muscle strength parameters will be analyzed using appropriate statistical methods.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Normal BMD | – | –Postmenopausal women with normal bone mineral density based on dual-energy X-ray absorptiometry (DEXA) T-scores. |
| Osteopenia | – | –Postmenopausal women with osteopenia defined by dual-energy X-ray absorptiometry (DEXA) T-scores. |
| Osteoporosis | – | –Postmenopausal women with osteoporosis defined by dual-energy X-ray absorptiometry (DEXA) T-scores. |
Who may qualify
- Ages
- 50 to 65 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will consist of postmenopausal women aged between 50 and 65 years who attend the outpatient clinic and meet the inclusion criteria. Participants will be classified into normal, osteopenic, and osteoporotic groups based on bone mineral density measurements obtained by dual-energy X-ray absorptiometry (DEXA).
Key inclusion criteria (1 listed)
- Postmenopausal women aged between 50 and 65 years Availability of bone mineral density measurement by dual-energy X-ray absorptiometry (DEXA) Willingness to participate in the study
Key exclusion criteria (1 listed)
- Presence of malignancy Chronic kidney disease Chronic liver disease Neuromuscular disorders Recent major surgery or trauma Use of medications affecting bone or muscle metabolism
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Relationship between serum myostatin and irisin levels and bone mineral density (T-score)
Time frame: Baseline
Serum myostatin and irisin levels will be measured from fasting venous blood samples, and bone mineral density will be assessed using dual-energy X-ray absorptiometry (DEXA). The relationship between these parameters will be evaluated.
2 secondary outcomes
Relationship between serum myostatin and irisin levels and muscle strength
Time frame: Baseline
Comparison of serum myostatin and irisin levels among bone mineral density groups
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Apr 2026.
Related trials for Osteoporosis, Osteopenia
Not yet recruiting
Exercise and Fall Prevention for Fracture Reduction
Osteopenia, Osteoporosis
RecruitingObservational study
A Study Evaluating the Performance of Using AI Software and Chest X-rays to Screen for Osteoporosis as Compared to Standard DXA Scans in Patients 50 Years and Older
Osteoporosis, Osteopenia
Active, not recruiting
Sickle Cell Disease (SCD) Bone Pain Study
Sickle Cell Disease, Sickle Cell Anemia
Active, not recruiting
Physical Activity Guarantees Bone Density.
Osteoporosis, Osteopenia
RecruitingPhase 4
The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation
Postmenopausal Osteoporosis, Postmenopausal Osteopenia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Zeynep Karakuzu Güngör, M.D principal investigator
Saglik Bilimleri Universitesi
Questions about this trial
What is this clinical trial studying?
An observational study of Osteoporosis, Osteopenia, run by Kanuni Sultan Suleyman Training and Research Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 9 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Zeynep Karakuzu Güngör, M.D (+905077750375, zeynepkarakuzu@hotmail.com.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Relationship between serum myostatin and irisin levels and bone mineral density (T-score) (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Apr 2026.